increasing use of PTFE grafts in the United States does not have any clinical justification. Background. In the United States, the use of polytertraflouroethylene (PTFE) graft compared with native Key words: haemodialysis; vascular access; arterioarteriovenous fistula (AVF ) for haemodialysis vascular venous fistula; PTFE graft; serum albumin; urea reducaccess has been increasing despite a greater than twotion ratio; dialysis adequacy fold higher incidence of thrombosis and infection associated with PTFE grafts. Methods. We studied 214 haemodialysis patients with not more than two revisions of their vascular access, Introduction to determine whether any relationship exists between the type of haemodialysis vascular access and dialysis In the United States, the use of polytetraflouroethylene dose assessed primarily by urea reduction ratio (per (PTFE ) grafts compared with native arteriovenous cent reduction in blood urea nitrogen concentration access for haemodialysis vascular access is increasing after a dialysis session). Serum albumin concentration without obvious explanation [1][2][3]. It is estimated that was used as a secondary outcome measure of dialysis at the end of 1993, 61% of American haemodialysis adequacy. Urea reduction ratio and predialysis serum patients had a PTFE graft while only 29% had a native albumin concentration were measured at onset of study AVF [1]. In fact, patients with incipient uraemia about and at 4-week intervals and mean values were calcu-to receive their first haemodialysis in the United States lated for each subject.
collection was done by the principal investigator and three intervals, for a total of four measurements, and a mean value calculated for each subject. co-investigators (J.D.M, J.J.M, A.F.) who followed a common interview technique to ensure accuracy.
Inclusion criteria were: ESRD treated by haemodialysis Secondary outcome-serum albumin concentration
thrice weekly via a surgically created vascular access for at least 4 months, age Á20 years, not more than one vascular Predialysis serum albumin concentration was used as a access in the arm with the current vascular access, not more secondary outcome measure of dialysis adequacy [9, 10] . than two prior vascular access revisions in the current access Serum albumin was measured at onset of study, and at (angioplasty, medical thrombolysis or surgery), absence of 4-week intervals for a total of four measurements and a infection (fever or leukocytosis), present treatment with mean value calculated for each subject. recombinant erythropoietin for at least 4 months, informed consent, no severe co-morbidity known to cause anaemia Statistical analysis (i.e., sickle cell disease). The study was approved by the Institutional Review Board.
Comparison of continuous and categorical variables between Exclusion criteria were: patient refusal, current vascular PTFE graft and native AVF groups was performed using access in the thigh or a temporary dialysis catheter, infection Student's t test and x2-test, respectively. with human immunodeficiency virus, on treatment or being
We categorized patients according to whether URR was evaluated for any infection. Patients were also excluded if 65% or less or >65%, and whether serum albumin concenwithin the 10 weeks preceding enrollment they suffered: tration was ∏4 g/dl or >4 g/dl. Separate multiple logistic blood loss (gastrointestinal or vascular access), blood trans-regression analyses were performed using a URR >65% or fusion, hospitalization, infection (fever and leukocytosis), a serum albumin concentration >4 g/dl as the dependent missed dialysis treatment and early signoffs from dialysis.
variable. Each subject's type of vascular access was ascertained by Independent variables in each regression model included history, examination and patient records. Patients were fol-type of vascular access (PTFE=1, AVF=0) dry weight, lowed for 16 weeks. Patients were excluded during the study length of dialysis treatment, dialyser urea clearance, and the for: blood loss (gastrointestinal or dialyser-related ), hospital-variables in which the PTFE group differed significantly ization for any reason, infection, missed dialysis treatment, from the AVF group (Table 1) : age of vascular access, prior insistence on early termination of a dialysis session, or change access revision ( Yes=1, No=0), and location of access (fore in dialysis prescription (duration of treatment or surface area arm 1, upper arm=0). Patient age was included as an of dialyser).
independent variable in the analysis with serum albumin Information obtained from each patient included patient concentration >4 g/dl as the dependent variable. age, gender, race, cause and duration of ESRD, haemodiaSince patients were recruited from different dialysis facilitlysis prescription, type of vascular access, location of vascular ies, subgroup analyses, limited to comparison of continuous access (forearm or upperarm-using the elbow joint as and categorical variables between native AVF and PTFE demarcation), age of vascular access, number of revisions of graft groups, was performed among patients in each dialysis vascular access, interval since last vascular access revision to facility. Results of multiple logistic regression analyses include odds ratios, 95% confidence interval, and P values. onset of study, and maximum blood flow achieved during
In all analyses, a P value of P<0.05 was considered statisticthe four dialysis sessions when URR was measured. patients). A prior report using this patient cohort examined the relation between dialysis adequacy and body mass [12] .
Primary outcome-urea reduction ratio
The remaining 214 patients (118 males and 96 females), included 173 Blacks (81%), 26 Whites (12%), We calculated the URR (percent reduction in blood urea and 15 Hispanics (7%) of mean age 55.6±15.5 years nitrogen concentration after a dialysis session), employing (range 22-86 years). One hundred and eleven (52%) the formula:
of 214 subjects had a native AVF, while 103 (48%) between subjects with native AVF, or PTFE graft, is shown in Tables 1 and 2 . Diabetic patients were more Postdialysis BUN was measured 1 min after the end of haemodialysis. URR was measured at onset and at 4-week likely to have a PTFE graft than a native AVF (P= aTo onset of study. # Total does not add up to 100% because 29 (23%) was placed by seven other surgeons, and 20 (11%) subjects could not remember the operating surgeon.
0.005), while non-diabetic patients were more likely to located in the forearm in 128 (60%) subjects, and in the upper arm in 86 (40%) subjects. Eighty-eight (41%) get a native AVF than a PTFE graft.
of 214 vascular accesses were created by one surgeon, ESRD was attributed to hypertension in 98 subjects 45 (21%) of 214 were created by another surgeon, and (45%), diabetes mellitus in 67 subjects (31%), chronic 32 (15%) of 214 were created by a third surgeon. glomerulonephritis in 12 subjects (6%), systemic lupus Twenty-nine (23%) of 214 vascular accesses were estaberythematosus in six subjects (3%), autosomal dominlished by seven surgeons. Twenty subjects (11%) could ant polycystic kidney disease in three subjects (2%), not identify their vascular access surgeon, and this obstructive nephropathy in two subjects (1%), and information could not be independently obtained. unknown in 26 subjects (12%).
Only the three surgeons who each created >30 Mean duration of ESRD prior to study was 52±49 accesses (88,45,32) were included in the multiple months (range 4-248 months), and mean length of logistic regression analyses. One-hundred and thirteen prescribed dialysis treatment was 3.7±0.42 h (range (53%) of 214 subjects had no vascular access revision, 3-4.5 h). The group's mean URR was 70±7%, the while 76 (35%) of 214 subjects had one revision, and mean serum albumin concentration was 4.01±0.36 g/ 25 (12%) of 214 subjects have had two revisions. dl, and the mean haematocrit was 32±3.4%.
Mean interval between last revision and onset of study was 9.8±13.5 months (range 1-72 months). The Vascular access-related variables mean maximum blood flow (from patient to dialyser The mean age of all vascular accesses was 39±33 cartridge) was 404±40 ml/min (range 300-600 ml/min) and 15 gauge needles were used for cannulation of months (range 4-215 months). Vascular access was vascular access in all the dialysis facilities studied. Discussion
Comparison of subsets of patients in each dialysis facility yielded results equivalent to that of the entire Our major findings are that in patients with ESRD group. receiving haemodialysis, there was no relationship between the type of surgically created haemodialysis vascular access in use and key measures of dialysis Vascular access and dialysis adequacy adequacy such as URR and serum albumin concentraResults of multiple logistic regression analyses with a tion. We found equivalent blood flow in native AVFs URR >65%, or a serum albumin concentration >4 and PTFE grafts, an observation consistent with that gm/dl as the outcome variable are shown on Tables 3 reported by the United States Renal Data Systems and 4, respectively. There was no significant correlation ( USRDS) [1] . between type of vascular access and a URR >65%
Patients starting haemodialysis for ESRD are usually (P=0.67) ( Table 3) , or a serum albumin concentration referred by nephrologists to a vascular surgeon who above 4 g/dl (P=0.89) ( Table 4) , after adjustment for often independently decides whether to insert a PTFE other factors.
graft or create a native AVF. Conventional wisdom is that PTFE grafts are employed when in the surgeon's judgement a native AVF cannot be established.
Sample size and power
However, while the superiority of a native AVF over a PTFE graft in terms of lower incidence of thromAssuming an a of 0.05, an estimate of effect size using Solo Power Analysis [13] showed that our sample size boses/infection, and longer life span is well recognized [2, [4] [5] [6] 8] , there are no national guidelines in the US of 214 (native AVF=111 vs PTFE graft=103) has a power of 82% to detect a 2.75% point difference in for choosing the initial haemodialysis vascular access.
Purported clinical criteria for selecting the type of mean URR between the native AVF group and the PTFE group, if a difference existed.
haemodialysis vascular access include suitability of arm blood vessels for creation of a native AVF, estimated Also, the sample size of 214 had a power of 99.9% to detect a 5% point difference in mean URR between length of time before the start of dialysis (since PTFE grafts are usually ready for use in less time (1-3 weeks) the two groups, if a difference existed. than native AVF (4-8 weeks)), and the unsubstantiated American haemodialysis patients is being propelled by economic considerations and is detrimental to the assertion by many clinicians that PTFE grafts permit delivery of better dialysis than native AVF. general wellbeing of these patients. Multiple episodes of vascular access thromboses and infections will cumuUndermining the argument that choice of type of vascular access is predominantly determined by clinical latively result in underdialysis. Underdialysis not only shortens survival [1, 9, 10] , but leads to malnutrition factors, is the recent finding that use of PTFE grafts in the US is predicted by socioeconomic factors and [10], persistent anaemia [16] [17] [18] , and functional impairment [19] , resulting in frequent hospitalizations region of residence, even after adjustment for case mix differences [14] . Inferences from this study are that the that escalate healthcare costs [1, 10] .
Hospitalization accounts for almost 50% of the $11 selection of the type of haemodialysis vascular access is predominantly determined by financial considera-billion dollars spent annually for ESRD therapy in the US and 20-40% of these hospital admissions is for tions and other non-clinical variables [14] .
There is no evidence to suggest that creating a native vascular access thrombosis and dysfunction [1, 2, 7, 8] .
Significant cost savings can be achieved by encouraging AVF requires significantly more surgical skill and expertise than the placement of a PTFE graft. We do use of native AVF, hence the wasting of tens of millions of dollars on hospitalizations for multiple revisions of not know of an alternative explanation for the increasing use of PTFE grafts in the US.
thrombosed and/or infected PTFE grafts could be minimized. Also, a prospective study of patients receiving their first haemodialysis vascular access did not detect any Furthermore, increasing use of PTFE grafts limits the training of vascular surgeons in creation of native relationship between the type of vascular access placed and the time to initiation of dialysis [15] , an observa-AVFs, thus continuing the current trend into the future. However, a clue that the increasing use of tion at variance with the contention that a PTFE graft is selected because of the urgent need to commence PTFE grafts is potentially reversible, is that dialysis programs that have made a concerted effort to increase dialysis.
There are several limitations to our study. We the use of native AVFs succeeded [20] . acknowledge the possibility of confounding by indication since the reasons for the creation of one type of vascular access may be related to the outcomes we References assessed. However, the fact that non-clinical factors
